Effect of bicalutamide 150 mg on PSA progression in MO prostate cancer: Results from the Early Prostate Cancer program.

被引：0

作者：

See, W. A.

McLeod, D. G.

Iversen, P.

Wirth, M. P.

Armstrong, J.

Navani, S.

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] Walter Reed Army Med Ctr, Washington, DC 20307 USA

[3] Rigshosp, DK-2100 Copenhagen, Denmark

[4] Tech Univ Dresden, D-8027 Dresden, Germany

[5] AstraZeneca, Macclesfield, Cheshire, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：247S / 247S

页数：1

共 50 条

[1] Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer
See, W
Iversen, P
Wirth, M
McLeod, D
Garside, L
Morris, T
EUROPEAN UROLOGY, 2003, 44 (05) : 512 - 517
[2] The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer
Iversent, Peter
Roder, Martin Andreas
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (03) : 361 - 369
[3] Bicalutamide 150 mg: Practical prescribing in patients with early prostate cancer
Anderson, J
BJU INTERNATIONAL, 2004, 94 (06) : 758 - 759
[4] Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer - Editorial comment
Hammerer, PG
EUROPEAN UROLOGY, 2003, 44 (05) : 517 - 518
[5] Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme
Tyrrell, CJ
Payne, H
See, WA
McLeod, DG
Wirth, MP
Iversen, P
Armstrong, J
Morris, C
RADIOTHERAPY AND ONCOLOGY, 2005, 76 (01) : 4 - 10
[6] Bicalutamide 150 mg in addition to standard care delays progression to bone metastases in patients with locally advanced prostate cancer: Analyses from the second analysis of the Early Prostate Cancer program
See, W
McLeod, DG
Wirth, MP
Iversen, P
Morris, T
Armstrong, J
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S286 - S287
[7] The bicalutamide Early Prostate Cancer Program: Demography
See, WA
McLeod, D
Iversen, P
Wirth, M
UROLOGIC ONCOLOGY, 2001, 6 (02): : 43 - 47
[8] Adjuvant hormonal treatment for prostate cancer: The Bicalutamide Early Prostate Cancer Program
Wirth, MP
Froehner, M
ONCOLOGY, 2003, 65 : 1 - 4
[9] Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years
Wirth, MP
See, WA
McLeod, DG
Iversen, P
Morris, T
Carroll, K
JOURNAL OF UROLOGY, 2004, 172 (05): : 1865 - 1870
[10] Adjuvant bicalutamide 150 mg significantly improves progression-free survival following radiotherapy for early prostate cancer
Tyrrell, C
See, WA
McLeod, D
Wirth, MP
Iversen, P
Garside, L
JOURNAL OF UROLOGY, 2003, 169 (04): : 440 - 440

← 1 2 3 4 5 →